|
NCI: Posted on Tuesday, November 29, 2011 2:45 PM
Researchers from NCI’s Center for Cancer Research (CCR) led by Dr. Hisataka Kobayashi have developed a new type of targeted anticancer treatment using photoimmunotherapy—a light-activated “nano-bomb” bound to amonoclonal antibody (mAb) that delivers the cellular disruptor to tumor cells. In experiments in cells grown in the laboratory and in mouse models, the treatment effectively killed cancer cells that had an excess of a protein targeted by the mAb on their surfaces but spared normal cells. |
|
|
NCI: Posted on Tuesday, November 29, 2011 2:16 PM
New research indicates that a protein called TWIST plays a key role in the aggressiveness and progression of breast cancers by regulating estrogen receptor (ER) expression. This discovery may ultimately open the door to new treatments for ER-negative breast cancers, which are more aggressive and harder to treat than ER-positive breast cancers, said the researchers who led the study. The findings, from investigators at the Johns Hopkins University School of Medicine and the University Medical Center Utrecht in the Netherlands, were published online November 7 in |
|
|
NCI: Posted on Thursday, November 24, 2011 12:13 AM
The number of long-term cancer survivors in the United States is rising, as is the number of people who are overweight or obese, raising the specter that excess pounds could diminish length and quality of life for many who have survived cancer.Video produced and edited by Sarah Curry and Natalie Giannosa Obesity has been linked with increased risks of recurrenceand death in several cancers, including common cancers such as |
|
|
NCI: Posted on Thursday, November 24, 2011 12:04 AM
When it comes to understanding the connections between obesity and cancer, one thing is clear: It's complicated. In an effort designed to address this complexity, NCI launched the Transdisciplinary Research on Energetics and Cancer (TREC) initiative in 2005. TREC is a multicenter program that brings together investigators from diverse disciplines, ranging from biochemistry and molecular biology to behavioral science and urban planning, to understand the obesity-cancer link."
The TREC initiative challenged the research community to look at this problem from a very different approach and to broaden scientific partnerships in a truly transdisciplinary way," said Dr. |
|
|
NCI: Posted on Wednesday, November 23, 2011 11:48 PM
Concern about the public-health consequences of obesity has risen as its prevalence has increased worldwide. Obesity rates have more than doubled since 1980, according to the World Health Organization. In the United States alone, the 2007–2008 National Health and Nutrition Examination Survey results show that 34.2 percent of adults 20 years of age or older are overweight, 33.8 percent are obese, and 5.7 percent are extremely obese. In 1988–1994, in contrast, only 22.9 percent of adults were obese. |
|
|
NCI: Posted on Thursday, November 03, 2011 6:28 PM
Results of a study of men who have sex with men revealed that vaccination with the human papillomavirus (HPV) vaccine Gardasil, which protects against HPV types 6, 11, 16, and 18, reduced their risk of persistent anal HPV infection and decreased the incidence of anal intraepithelial neoplasia, a lesion known to precede anal cancer. The findings were published October 27 in the New England Journal of Medicine.
The incidence of anal cancer has been growing by around 2 percent a year in the general population. |
|
|
NCI: Posted on Thursday, November 03, 2011 6:01 PM
WOW! THIS WILL BE A SURPRISE TO ALL THOSE WHO TAKE TAMOXIFEN. Nwaokai-Beecham
In addition, 5 years of sequential treatment—either 2 years of letrozole followed by 3 years of tamoxifen or 2 years of tamoxifen followed by 3 years of letrozole—was not better than 5 years of letrozole alone at preventing recurrence or death. |
|
|
NCI: Posted on Thursday, November 03, 2011 5:45 PM
Annual screening for lung cancer using a standard chest x-ray does not reduce the risk of dying from lung cancer when compared with no annual screening, according to findings from the NCI-led Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial. The results from a median of nearly 12 years of follow-up were published online October 26 in JAMA. Participants in the trial who were randomly assigned to receive an annual chest x-ray for 4 consecutive years had nearly the same mortality rate from lung cancer as participants randomly assigned to receive usual care—that is, care they would typically receive in their own community. |
|
|
NCI: Posted on Thursday, November 03, 2011 5:37 PM
Patients who have received a solid organ transplant, such as a kidney, lung, or heart transplant, are twice as likely to develop cancer as the general population, and the risk extends to a broad range of cancers, according toresearch published November 1 in JAMA. Doctors have known since the early days of organ transplantation that cancer is a possible complication of this often life-saving procedure. The new study gives researchers the first overview of cancer risk patterns in a large population of solid organ transplant recipients in the United States, including risk patterns for less common cancers. |
|
|
SHORTAGES INCLUDE CANCER MEDS: Posted on Thursday, November 03, 2011 5:17 PM
BREAKING NEWS:
FOR MORE INFORMATION ON CANCER MEDICATIONS BUY THE BOOK "MEMOIRS OF CANCER," HERE |
|
